He is known for his fundamental and translational research in nanomedicine and drug delivery, especially in polymeric and nanomaterials' cell and immune safety, and as an inventor of nanosystems for tissue-specific targeting.
[3] He then joined Stanley Stewart Davis' laboratory at the Department of Pharmaceutical Sciences, University of Nottingham for postdoctoral training in advanced drug delivery system engineering.
[7][19][20] His current work includes the development of a concomitant long-term computational network assessment of genomics and epigenomic factors in inter-individual variations to nanomedicine performance and cell re-programming.
[4] Resulting from his PhD research, Moghimi introduced the opsonin-dysopsonin hypothesis, suggesting a regulatory role for certain blood proteins in limiting nanoparticle uptake by macrophages.
[22][23] Moghimi has developed a range of injectable nanosystems, including an early prototype of splenotropic and lymphotropic nanoparticles based on the concept of steric stabilisation and surface engineering with block copolymers.
[24][25] A research group led by Moghimi developed NanoLigand Carriers,[26] induced self-assemblies of phage-derived display peptides that on intravenous injection rapidly target two receptors on the blood brain-barrier.
[34] His research also explained the molecular basis of complement activation by polyethylene glycol, a polymer that is used widely for prolonging the blood circulation time of proteins and particulate drug carriers.
[38] He has challenged the validity of the CARPA (Complement Activation Related Pseudo-Allergy) hypothesis, and proposed a working mechanism explaining idiosyncratic nanomedicine-mediated anaphylaxis seen in patients.
[41] In 2020, Moghimi commented on the sudden closure of the Centers of Cancer Nanotechnology Excellence in the United States, and called for support in curiosity driven research in fundamental nanomedicine even in the absence of immediate obvious benefits to society.